-$3.01 EPS Expected for Beigene Ltd (NASDAQ:BGNE) This Quarter

Share on StockTwits

Equities research analysts expect that Beigene Ltd (NASDAQ:BGNE) will announce earnings of ($3.01) per share for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Beigene’s earnings, with the highest EPS estimate coming in at ($2.50) and the lowest estimate coming in at ($3.39). Beigene posted earnings per share of ($2.92) during the same quarter last year, which suggests a negative year-over-year growth rate of 3.1%. The business is expected to announce its next quarterly earnings results on Thursday, August 8th.

According to Zacks, analysts expect that Beigene will report full-year earnings of ($12.95) per share for the current year, with EPS estimates ranging from ($16.01) to ($9.73). For the next year, analysts forecast that the company will report earnings of ($12.30) per share, with EPS estimates ranging from ($14.78) to ($8.21). Zacks’ earnings per share calculations are an average based on a survey of sell-side research analysts that cover Beigene.

Beigene (NASDAQ:BGNE) last posted its quarterly earnings results on Thursday, May 9th. The company reported ($2.81) earnings per share for the quarter, beating the consensus estimate of ($3.15) by $0.34. The firm had revenue of $77.83 million for the quarter, compared to analyst estimates of $55.79 million. Beigene had a negative return on equity of 44.75% and a negative net margin of 302.58%. Beigene’s quarterly revenue was up 139.2% on a year-over-year basis. During the same period in the previous year, the firm earned ($2.03) earnings per share.

A number of research analysts have commented on BGNE shares. Zacks Investment Research upgraded Beigene from a “sell” rating to a “hold” rating in a research note on Tuesday, May 7th. Maxim Group set a $170.00 target price on Beigene and gave the company a “buy” rating in a research note on Thursday, February 28th. Sanford C. Bernstein started coverage on Beigene in a research note on Tuesday, June 4th. They issued an “outperform” rating and a $201.00 target price on the stock. Morgan Stanley boosted their target price on Beigene from $200.00 to $210.00 and gave the company an “overweight” rating in a research note on Tuesday, May 14th. Finally, BidaskClub upgraded Beigene from a “sell” rating to a “hold” rating in a research note on Friday, June 21st. Two analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. Beigene has an average rating of “Buy” and a consensus price target of $182.28.

In other news, insider Xiaobin Wu sold 5,955 shares of the company’s stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $124.52, for a total transaction of $741,516.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Donald W. Glazer sold 15,027 shares of the company’s stock in a transaction dated Monday, May 13th. The stock was sold at an average price of $125.11, for a total value of $1,880,027.97. Following the sale, the director now owns 3,911,518 shares of the company’s stock, valued at approximately $489,370,016.98. The disclosure for this sale can be found here. In the last quarter, insiders have sold 63,236 shares of company stock valued at $8,286,319. 13.30% of the stock is currently owned by corporate insiders.

Several institutional investors and hedge funds have recently added to or reduced their stakes in BGNE. Neuburgh Advisers LLC bought a new stake in shares of Beigene during the 4th quarter worth about $27,000. Advisor Group Inc. boosted its stake in shares of Beigene by 301.4% during the 4th quarter. Advisor Group Inc. now owns 285 shares of the company’s stock worth $40,000 after acquiring an additional 214 shares in the last quarter. PNC Financial Services Group Inc. bought a new stake in shares of Beigene during the 4th quarter worth about $46,000. Quadrant Capital Group LLC boosted its stake in shares of Beigene by 131.8% during the 1st quarter. Quadrant Capital Group LLC now owns 364 shares of the company’s stock worth $47,000 after acquiring an additional 207 shares in the last quarter. Finally, LS Investment Advisors LLC bought a new stake in shares of Beigene during the 4th quarter worth about $71,000.

NASDAQ:BGNE traded up $3.95 during trading hours on Wednesday, hitting $124.97. 6,531 shares of the company’s stock traded hands, compared to its average volume of 318,380. The stock has a market cap of $5.76 billion, a price-to-earnings ratio of -10.29 and a beta of 1.11. Beigene has a twelve month low of $105.19 and a twelve month high of $194.56. The company has a debt-to-equity ratio of 0.14, a quick ratio of 7.47 and a current ratio of 7.52. The stock has a fifty day moving average price of $124.42.

About Beigene

BeiGene, Ltd., a commercial-stage biotechnology company, develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer in the People's Republic of China, the United States, and internationally. Its commercial products include ABRAXANE, a chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancers; REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma in combination with dexamethasone; and VIDAZA, a pyrimidine nucleoside analog for the treatment of intermediate-2 and myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia with 20% to 30% blasts and multi-lineage dysplasia.

Recommended Story: Fundamental Analysis and Choosing Stocks

Get a free copy of the Zacks research report on Beigene (BGNE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Nemetschek  PT Set at €52.33 by Baader Bank
Nemetschek PT Set at €52.33 by Baader Bank
HSBC Analysts Give SGL Carbon  a €7.00 Price Target
HSBC Analysts Give SGL Carbon a €7.00 Price Target
Royal Bank of Canada Analysts Give Peugeot  a €19.00 Price Target
Royal Bank of Canada Analysts Give Peugeot a €19.00 Price Target
zooplus  PT Set at €205.00 by JPMorgan Chase & Co.
zooplus PT Set at €205.00 by JPMorgan Chase & Co.
Stock Traders Buy High Volume of Put Options on Kansas City Southern
Stock Traders Buy High Volume of Put Options on Kansas City Southern
Canfor  Downgraded by Raymond James to Outperform
Canfor Downgraded by Raymond James to Outperform


 
© 2006-2019 Zolmax.